Physiogenex will present at the NASH-TAG 2018 in Park City, UT, USA, January 4th-6th, 2018.
Dr. François Briand, Director of Research and Business Development, will be presenting a poster about the effects of obeticholic acid and elafibranor in the Diet-Induced NASH (DIN) hamster model.
Looking forward to meet you there!
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.
Please visit our website for more information